Distinctive features of the main classes: mTOR, PI3K, dual inhibitors & AKT

Date 01 March 2014
Event Signalling Pathways in Cancer 2014
Session Clinical development of PI3K/AKT/mTOR inhibitors
Topics Drug Development
Presenter Jordi Rodon
Authors J. Rodon
  • Barcelona/ES